CF PharmTech repurchases 20,000 H shares, treasury stock rises to 542,000

Bulletin Express04-02

On 2 April 2026, CF PharmTech, Inc. filed a Next Day Disclosure Return with the Hong Kong Stock Exchange detailing the on-market buyback of 20,000 H shares.

The shares were repurchased at prices between HKD 22.68 and HKD 23.08, with a volume-weighted average of HKD 22.83, for a total consideration of HKD 0.46 million.

Following the transaction, the company’s issued share capital (excluding treasury shares) fell by 20,000 to 301.68 million, a reduction of 0.0066%. Treasury shares increased from 522,000 to 542,000, while total issued shares remained unchanged at 302.22 million because no repurchased shares have been cancelled.

The buyback was executed under the mandate approved on 16 December 2025, which authorises the repurchase of up to 30.22 million shares. Aggregate repurchases under this mandate now stand at 542,000 shares, representing 0.18% of the issued shares at the time the mandate was granted.

Under Hong Kong listing rules, CF PharmTech is subject to a moratorium on issuing new shares or disposing of treasury shares until 2 May 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1186649255?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-02 18:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186649255","market":"hk","top_or_hot":-1,"title":"CF PharmTech repurchases 20,000 H shares, treasury stock rises to 542,000","media":"Bulletin Express","content":"<p>On 2 April 2026, CF PharmTech, Inc. filed a Next Day Disclosure Return with the Hong Kong Stock Exchange detailing the on-market buyback of 20,000 H shares.</p>\n<p>The shares were repurchased at prices between HKD 22.68 and HKD 23.08, with a volume-weighted average of HKD 22.83, for a total consideration of HKD 0.46 million.</p>\n<p>Following the transaction, the company’s issued share capital (excluding treasury shares) fell by 20,000 to 301.68 million, a reduction of 0.0066%. Treasury shares increased from 522,000 to 542,000, while total issued shares remained unchanged at 302.22 million because no repurchased shares have been cancelled.</p>\n<p>The buyback was executed under the mandate approved on 16 December 2025, which authorises the repurchase of up to 30.22 million shares. Aggregate repurchases under this mandate now stand at 542,000 shares, representing 0.18% of the issued shares at the time the mandate was granted.</p>\n<p>Under Hong Kong listing rules, CF PharmTech is subject to a moratorium on issuing new shares or disposing of treasury shares until 2 May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF PharmTech repurchases 20,000 H shares, treasury stock rises to 542,000</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF PharmTech repurchases 20,000 H shares, treasury stock rises to 542,000\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-02 18:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On 2 April 2026, CF PharmTech, Inc. filed a Next Day Disclosure Return with the Hong Kong Stock Exchange detailing the on-market buyback of 20,000 H shares.</p>\n<p>The shares were repurchased at prices between HKD 22.68 and HKD 23.08, with a volume-weighted average of HKD 22.83, for a total consideration of HKD 0.46 million.</p>\n<p>Following the transaction, the company’s issued share capital (excluding treasury shares) fell by 20,000 to 301.68 million, a reduction of 0.0066%. Treasury shares increased from 522,000 to 542,000, while total issued shares remained unchanged at 302.22 million because no repurchased shares have been cancelled.</p>\n<p>The buyback was executed under the mandate approved on 16 December 2025, which authorises the repurchase of up to 30.22 million shares. Aggregate repurchases under this mandate now stand at 542,000 shares, representing 0.18% of the issued shares at the time the mandate was granted.</p>\n<p>Under Hong Kong listing rules, CF PharmTech is subject to a moratorium on issuing new shares or disposing of treasury shares until 2 May 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"","article_id":"1186649255","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186649255","pubTimestamp":1775126584,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On 2 April 2026, CF PharmTech, Inc. filed a Next Day Disclosure Return with the Hong Kong Stock Exchange detailing the on-market buyback of 20,000 H shares. The shares were repurchased at prices...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02652":"长风药业"},"translate_title":"CF PharmTech回购2万股H股库存股升至54.2万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1},"content_text":"On 2 April 2026, CF PharmTech, Inc. filed a Next Day Disclosure Return with the Hong Kong Stock Exchange detailing the on-market buyback of 20,000 H shares.\nThe shares were repurchased at prices between HKD 22.68 and HKD 23.08, with a volume-weighted average of HKD 22.83, for a total consideration of HKD 0.46 million.\nFollowing the transaction, the company’s issued share capital (excluding treasury shares) fell by 20,000 to 301.68 million, a reduction of 0.0066%. Treasury shares increased from 522,000 to 542,000, while total issued shares remained unchanged at 302.22 million because no repurchased shares have been cancelled.\nThe buyback was executed under the mandate approved on 16 December 2025, which authorises the repurchase of up to 30.22 million shares. Aggregate repurchases under this mandate now stand at 542,000 shares, representing 0.18% of the issued shares at the time the mandate was granted.\nUnder Hong Kong listing rules, CF PharmTech is subject to a moratorium on issuing new shares or disposing of treasury shares until 2 May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1186649255","isCrawlerRequest":true}